These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1467385)

  • 41. Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients.
    Hunt JI; Singh H; Simpson GM
    J Clin Psychiatry; 1988 Jul; 49(7):258-61. PubMed ID: 2899071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fluphenazine enanthate in the outpatient treatment of late paraphrenia.
    Raskind M; Alvarez C; Herlin S
    J Am Geriatr Soc; 1979 Oct; 27(10):459-63. PubMed ID: 469146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.
    Wistedt B
    Acta Psychiatr Scand; 1981 Jul; 64(1):65-84. PubMed ID: 7032224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism.
    Thaker GK; Wagman AM; Kirkpatrick B; Tamminga CA
    Biol Psychiatry; 1989 Jan; 25(1):75-86. PubMed ID: 2563233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z; Britvić D; Vuković O; Ille T
    Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prolactin response to submaximal stimulation by TRH in nonaffective psychoses.
    Spoov J; Bredbacka PE; Appelberg B; Katila H; Karonen SL; Rimón R; Sarna S
    Biol Psychiatry; 1991 Feb; 29(3):204-10. PubMed ID: 1673063
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pilot study of a structured interview addressing sexual function in men with schizophrenia.
    Burke MA; McEvoy JP; Ritchie JC
    Biol Psychiatry; 1994 Jan; 35(1):32-5. PubMed ID: 8167201
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relation of plasma prolactin to clinical response in schizophrenic patients.
    Gruen PG; Sachar EJ; Altman N; Langer G; Tabrizi MA; Halpern FS
    Arch Gen Psychiatry; 1978 Oct; 35(10):1222-7. PubMed ID: 29592
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of haloperidol and Trifluoperazine. (A double-blind, controlled study on chronic schizophrenic outpatients).
    Luckey WT; Schiele BC
    Dis Nerv Syst; 1967 Mar; 28(3):181-6. PubMed ID: 4381424
    [No Abstract]   [Full Text] [Related]  

  • 52. Differential effects of neuroleptic agents on the pituitary-gonadal axis in men.
    Brown WA; Laughren TP; Williams B
    Arch Gen Psychiatry; 1981 Nov; 38(11):1270-2. PubMed ID: 6118109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of outcome in first-episode schizophrenia.
    Lieberman JA
    J Clin Psychiatry; 1993 Mar; 54 Suppl():13-7. PubMed ID: 8097192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia.
    Forman SD; Bissette G; Yao J; Nemeroff CB; van Kammen DP
    Schizophr Res; 1994 Apr; 12(1):43-51. PubMed ID: 8018584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children.
    Engelhardt DM; Polizos P; Waizer J; Hoffman SP
    J Autism Child Schizophr; 1973; 3(2):128-37. PubMed ID: 4583792
    [No Abstract]   [Full Text] [Related]  

  • 56. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients.
    Abel KM; O'Keane V; Murray RM
    Br J Psychiatry; 1996 Jan; 168(1):57-60. PubMed ID: 8770429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low serum neuroleptic levels predict relapse in schizophrenic patients.
    Brown WA; Laughren T; Chisholm E; Williams BW
    Arch Gen Psychiatry; 1982 Sep; 39(9):998-1000. PubMed ID: 6126172
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Costs and benefits of two doses of fluphenazine.
    Marder SR; Van Putten T; Mintz J; McKenzie J; Lebell M; Faltico G; May PR
    Arch Gen Psychiatry; 1984 Nov; 41(11):1025-9. PubMed ID: 6437365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Peters JL
    Arch Gen Psychiatry; 1995 Aug; 52(8):673-8. PubMed ID: 7543265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.